Does 18F-PSMA-1007 PET/CT Effectively Detect Among Patients with Suspected Prostate Cancer-Case Report

Min-Che Tung1, Neng-Chuan Tseng2, Chao-Yu Hsu1, Wei-Chun Weng1, Henry Li-Hua Huang1, Yi-Sheng Lin1, Ya-Ting Huang3, Yen-Chuan Ou1,4

1Division of Urology, Department of Surgery, Tungs’ Taichung Metro Harbor Hospital, Taichung, Taiwan
2Division of Nuclear Medicine, Tungs’ Taichung Metro Harbor Hospital, Taichung, Taiwan
3Primo Biotechnology Co., Ltd, Taipei, Taiwan
4Department of Research, Tungs’ Taichung Metro Harbor Hospital, Taichung, Taiwan

This case report was presented at the 2024 Annual Meeting of the Taiwan Urological Association(TUA).

The current case series aimed to detect suspected intra-prostate lesions using PSMA PET and evaluate the biodistribution in normal organs and imaging visibility at different time points (60, 90, and 180 minutes post-injection).

This case was a 56-year-old male, in whom mpMRI and 18F-PSMA-1007 PET/CT detected lesions in both the left and right lobes of the prostate. Pathologic analysis confirmed the lesions as ISUP grade II with a Gleason score of 3+4, demonstrating high concordance between imaging findings and pathologic results.The case report suggests that the 60-minute PET/CT scan with 18F-PSMA-1007 was sufficient to detect intra-prostatic lesions, with malignant lesions having a higher uptake than benign lesions. However, further studies are needed to validate these results.